Delivery Order SPE2DB25D3002-SPE2DB25FLRDW
- Not listed
- The Defense Logistics Agency awarded a $5,769.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen (semaglutide) on August 1, 2025, with completion targeted for August 4, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections, with a ceiling value of $1,143.87 and an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery...
- The Defense Logistics Agency awarded a $14,615.04 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on July 18, 2025, with completion scheduled for July 21, 2025. This contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $2,724.55 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injectors. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government...
- The Defense Logistics Agency awarded a $69,595.58 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award, and is scheduled for completion by August 6, 2025. Performance will be executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under a child contract vehicle,...
- The Defense Logistics Agency awarded a $37,571.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections. This delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a small-value pharmaceutical procurement under a larger indefinite delivery contract framework. The contract was competitively awarded with no set-aside designation, and performance will be executed from...
- The Defense Logistics Agency awarded a delivery order valued at $2,015.96 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen (semaglutide injection) on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate...
- The Defense Logistics Agency awarded a $1,871.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive delivery order is issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections valued at $10,445.54 on August 7, 2025, with completion scheduled for August 8, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.999 billion prime vendor agreement...
- The Defense Logistics Agency awarded a delivery order contract valued at $3,813.85 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This competitive, firm fixed-price delivery order is set to be completed by July 28, 2025, with performance occurring at the company's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child order issued under a larger contract vehicle supporting the federal medical...
- SPE2DB25D3002Indefinite Delivery Contract
- SPE2DB25D3002-SPE2DB25FLRDWDelivery Order
The Defense Logistics Agency awarded a $6,146.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen (semaglutide injection) with an ultimate completion date of August 4, 2025. This non-set-aside competitive award represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order supports the Defense Health Agency's pharmaceutical supply chain by providing a diabetes and weight management medication to military and veteran healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense through competitive contract awards. The award reflects the company's ongoing role as a primary pharmaceutical vendor for global military healthcare programs, delivering both brand-name and generic medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 8/1/25 |